i Fraumeni syndrome (LFS) (OMIM 151623) is a rare autosomal-dominant genetic disorder inherited by means of germline TP53 mutations. Carriers have a high lifetime risk of developing multiple early-onset childhood and adult cancers, including soft-tissue and bone sarcomas, central nervous system tumors, adrenocortical tumors, breast cancer, and leukemia.
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i Fraumeni syndrome (LFS) (OMIM 151623) is a rare autosomal-dominant genetic disorder inherited by means of germline TP53 mutations. Carriers have a high lifetime risk of developing multiple early-onset childhood and adult cancers, including soft-tissue and bone sarcomas, central nervous system tumors, adrenocortical tumors, breast cancer, and leukemia. 1 In a recent large
French series, 332 of 415 carriers were cancer affected and the more prevalent tumors were breast carcinoma (31.1%), soft-tissue sarcoma (18.8%), osteosarcoma (9.6%), central nervous system tumor (7.7%), and adrenocortical carcinoma (7.7%). 2 It has been observed that there is substantial clinical tumor heterogeneity in LFS and additional tumor types have been described in LFS families. 3, 4 Nevertheless, to our knowledge, the occurrence of thyroid carcinoma in LFS carriers has not been evaluated in the literature. A trial with fluorodeoxyglucose-positron emission tomography/ computed tomography scans for cancer screening in LFS carriers identified 2 cases of papillary thyroid carcinoma in 15 asymptomatic carriers. 5 Recently, a case report of a Spanish patient with papillary thyroid carcinoma at age 36 years was published. 6 Regarding sporadic thyroid cancer, based on the Surveillance, Epidemiology, and End Results database, approximately 1.1% of men and women will receive a diagnosis of thyroid cancer at some point during their lifetime, with a median age at diagnosis of 51 years. 7 In Brazil, the incidence of spo- . All the cases were histologically classified as papillary carcinomas, with 2 of them exhibiting follicular variant. The most common other cancers in the patients with thyroid carcinoma were breast cancer (5 patients) and soft-tissue sarcoma (2 patients).
IMPORTANCE
CONCLUSIONS AND RELEVANCE Thyroid carcinoma may be associated with the Brazilian founder TP53 p.R337H mutation. Knowledge about this genotype/phenotype correlation is relevant to adjusting the LFS screening recommendations to these specific carriers.
radic thyroid cancer for men and women is 1.2 and 5.3 cases per 100 000 per year, respectively. 8 Although the majority of thyroid cancers are sporadic, some hereditary syndromes are associated with high risk for thyroid cancer, such as adenomatous polyposis, Cowden syndrome, and tuberous sclerosis, but not LFS.
9
The incidence of LFS has been estimated as 1 in 5000 live births worldwide. Studies from the south and southeast of Brazil indicate that the incidence of LFS in these regions is much higher, and mainly due to a founder germline TP53 mutation in the oligomerization domain (exon 10) (c.1010G>A, p. Arg337His), which occurs in approximately 1 in 300 newborns (0.3%). 10 The tumor profile among Brazilian carriers is similar to classic DNA-binding domain mutations found elsewhere in the world, but some age difference and a higher risk for other types of tumors may exist. Because thyroid cancer is not part of the core LFS tumor spectrum, the aim of this study was to determine the pattern of its occurrence in this specific population. 
Methods

Results
A total of 193 TP53 p.R337H mutation carriers were identified. In this analysis, breast cancer and soft-tissue sarcoma were also the most prevalent tumors in adults, and, interestingly, thyroid cancer was observed in unusual prevalence. Among 193 TP53 p.R337H mutation-positive patients from 58 families, 101 were cancer affected and 11 of these had the diagnosis of thyroid carcinoma (10.9%): 3 men and 8 women. The overall mean age at diagnosis was 44 years (median [SD], 43 [14.77] years). Five of 58 families (9%) had at least 1 family member with thyroid carcinoma: we observed 5 cases in 1 family, 3 cases in another family, and 3 more families with 1 case each. All the cases were histologically classified as papillary carcinomas, with 2 of them exhibiting follicular variant (Table  and eFigures 
Key Points
Question Is thyroid carcinoma related to Li Fraumeni syndrome?
Findings In this cohort of 193 Brazilian patients with Li Fraumeni syndrome carrying the founder TP53 p.R337H mutation, thyroid carcinoma was observed in 11 of 101 cancer-affected patients.
Meaning Thyroid carcinoma is a frequent cancer in TP53 p.R337H mutation carriers, suggesting the need to include thyroid imaging in Li Fraumeni syndrome screening protocol. Our results encourage further studies to elucidate whether thyroid cancer is related to LFS, as it is the fifth most prevalent tumor in women. Its incidence is a sporadic event in families with this cancer predisposition syndrome. Defining this issue would contribute to improving clinical and genetic management of these patients with thyroid cancer.
Of 101 p.R337H TP53 mutation-carrying family members with cancer in our study, 11 had thyroid cancer (10.9%).
Although it is an uncommon manifestation of LFS in general, our findings revealed that thyroid carcinoma appears to be a component of the spectrum of tumors in carriers with the founder TP53 p.R337H mutation.
Conclusions
Our results show that thyroid carcinoma may be a component of LFS. Therefore, these findings strengthen the importance of early and regular thyroid imaging screening in individuals with the founder TP53 p.R337H mutation in Brazilian carriers, particularly among those with a family history of thyroid cancer. This supplementary material has been provided by the authors to give readers additional information about their work.
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